Featured Research

from universities, journals, and other organizations

Ovarian cancer treatment discovered by researchers

Date:
June 19, 2014
Source:
St. Joseph's Hospital and Medical Center
Summary:
A new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur, research shows. In addition, this breakthrough showed a trend in improving survival although these data are not yet mature. "This is an exciting new targeted medication in treating recurrent ovarian cancer. Recurrent ovarian cancer is almost always fatal and new treatments are desperately needed," said one researcher.

Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on tumor shrinkage and delaying cancer progression, research shows.
Credit: © Kurhan / Fotolia

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. In addition, this breakthrough showed a trend in improving survival although these data are not yet mature.

Trebananib (formally known as AMG 386; Amgen) is a first-in-class peptide-Fc fusion protein (or peptibody) that targets angiogenesis (the growth of new blood vessels into cancerous tumors) by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor. This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin; Genentech).

Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on tumor shrinkage and delaying cancer progression.

Neither agent has shown a definitive increase in survival at this point. TRINOVA-1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

The trial was run by Professor Bradley J. Monk MD who directs the Division of Gynecologic Oncology at the University of Arizona Cancer Center at St. Joseph's in Phoenix and sponsored by Amgen. Dr. Monk's site also was the largest enrolling site in Arizona.

"This is an exciting new targeted medication in treating recurrent ovarian cancer. Recurrent ovarian cancer is almost always fatal and new treatments are desperately needed," said Dr. Monk. "TRINOVA-1 also showed that angiogenesis is a complex process in oncology and many new targets like angiopoietin 1/2 will allow us to more effectively inhibit the growth of new blood vessels that are necessary for cancer growth, metastases and progression. If we can stop cancers from growing by choking off their blood supply, we can help our patients feel better and live longer."

Amgen, the manufacturer of trebananib has not yet filed this agent with the US Food and Drug Administration (FDA) but has also enrolled two other ovarian cancer phase III trials that have not yet had reported results (TRINOVA-2 [NCT01281254], and TRINOVA-3 [NCT01493505]).

TRINOVA-2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA-3, also known as ENGOT -Ov2 and Gynecologic Oncology Group -- 3001, is studying the use of trebananib in front-line treatment adding it to carboplatin/paclitaxel. The results of these two additional trials are expected within a year and will hopefully add to a successful FDA application for approval making this agent available to American women with ovarian cancer.

The study will first be reported in the online editions of Lancet Oncology and then in the paper editions.


Story Source:

The above story is based on materials provided by St. Joseph's Hospital and Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan, Catherine Lhommé, Gary Richardson, Dolores Gallardo Rincón, Robert L Coleman, Thomas J Herzog, Christian Marth, Arija Brize, Michel Fabbro, Andrés Redondo, Aristotelis Bamias, Marjan Tassoudji, Lynn Navale, Douglas J Warner, Amit M Oza. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology, 2014; DOI: 10.1016/S1470-2045(14)70244-X

Cite This Page:

St. Joseph's Hospital and Medical Center. "Ovarian cancer treatment discovered by researchers." ScienceDaily. ScienceDaily, 19 June 2014. <www.sciencedaily.com/releases/2014/06/140619205442.htm>.
St. Joseph's Hospital and Medical Center. (2014, June 19). Ovarian cancer treatment discovered by researchers. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/06/140619205442.htm
St. Joseph's Hospital and Medical Center. "Ovarian cancer treatment discovered by researchers." ScienceDaily. www.sciencedaily.com/releases/2014/06/140619205442.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) — Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) — According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins